{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T03:41:48Z","timestamp":1772768508743,"version":"3.50.1"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"13","license":[{"start":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T00:00:00Z","timestamp":1753833600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T00:00:00Z","timestamp":1753833600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"MSK Cancer Center Support Grant","award":["P30  CA008748"],"award-info":[{"award-number":["P30  CA008748"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2025,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Mesothelioma of the tunica vaginalis testes (testicular mesothelioma [TM]) is a rare tumor, comprising less than 5% of mesotheliomas. Surgical intervention is the current standard of care, whereas the role of systemic therapies remains undefined.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We retrospectively reviewed 36 patients with pathologically confirmed TM treated at Memorial Sloan Kettering Cancer Center (MSK) between January 1996 to May 2023. Clinicopathologic data, treatments received, and clinical outcomes were reported. Surgical pathology samples, when available, underwent next-generation sequencing (NGS) using MSK-IMPACT. Overall survival (OS) was calculated by using the Kaplan\u2013Meier method.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Median age at diagnosis was 64 years (range 24\u201393). Histologically, 22 (61%) tumors were epithelioid, ten (28%) were biphasic, three (8%) were sarcomatoid, and one (3%) was unable to be further classified. Ten patients (28%) had metastatic disease at initial diagnosis, and 13 more (36%) eventually developed metastatic disease. Orchiectomy was performed in 34 (94%) patients and retroperitoneal lymph node dissection (RPLND) in 12 (33%); 15 (42%) received systemic therapy and five (14%) radiation therapy. Ten samples underwent somatic NGS: five (50%) had\n                      <jats:italic>CDKN2A\/B<\/jats:italic>\n                      , four (40%) had\n                      <jats:italic>NF2<\/jats:italic>\n                      , and two (20%) had\n                      <jats:italic>BAP1<\/jats:italic>\n                      alterations. At a median follow up of 3.5 years, median OS was 4.5 years.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>\n                      This is the largest single-institution series and genomic dataset for TM. We report unique clinicopathologic and genomic features that distinguish TM from other mesotheliomas, including a lower frequency of\n                      <jats:italic>BAP1<\/jats:italic>\n                      alterations. Owing to the rarity of this disease, further refinement of the sequence and necessity of surgical and systemic treatment is necessary.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1245\/s10434-025-17978-3","type":"journal-article","created":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T18:28:49Z","timestamp":1753900129000},"page":"10285-10293","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Clinicopathologic Characteristics and Clinical Outcomes of Patients with Testicular Mesothelioma"],"prefix":"10.1245","volume":"32","author":[{"given":"Prashasti","family":"Agrawal","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fady","family":"Baky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Judy","family":"Sarungbam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joel","family":"Sheinfeld","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Victor E.","family":"Reuter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Cercek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Garrett M.","family":"Nash","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer L.","family":"Sauter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William D.","family":"Travis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"suffix":"II","given":"Charles B.","family":"Simone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"George J.","family":"Bosl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marjorie G.","family":"Zauderer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard S.","family":"Matulewicz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7959-3018","authenticated-orcid":false,"given":"Michael","family":"Offin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,7,30]]},"reference":[{"key":"17978_CR1","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1016\/j.jtho.2021.09.012","volume":"17","author":"M Offin","year":"2022","unstructured":"Offin M, Yang SR, Egger J, et al. Molecular characterization of peritoneal mesotheliomas. J Thorac Oncol. 2022;17:455\u201360.","journal-title":"J Thorac Oncol."},{"key":"17978_CR2","doi-asserted-by":"publisher","first-page":"1428","DOI":"10.1016\/j.jtho.2022.08.017","volume":"17","author":"M Offin","year":"2022","unstructured":"Offin M, De Silva DL, Sauter JL, et al. Multimodality therapy in patients with primary pericardial mesothelioma. J Thorac Oncol. 2022;17:1428\u201332.","journal-title":"J Thorac Oncol."},{"key":"17978_CR3","doi-asserted-by":"publisher","first-page":"e565","DOI":"10.1016\/S2589-7500(21)00104-7","volume":"3","author":"MG Zauderer","year":"2021","unstructured":"Zauderer MG, Martin A, Egger J, et al. The use of a next-generation sequencing-derived machine-learning risk-prediction model (OncoCast-MPM) for malignant pleural mesothelioma: a retrospective study. Lancet Digit Health. 2021;3:e565\u201376.","journal-title":"Lancet Digit Health."},{"key":"17978_CR4","doi-asserted-by":"publisher","first-page":"113","DOI":"10.5858\/arpa.2010-0550-RS","volume":"136","author":"SS Chekol","year":"2012","unstructured":"Chekol SS, Sun CC. Malignant mesothelioma of the tunica vaginalis testis: diagnostic studies and differential diagnosis. Arch Pathol Lab Med. 2012;136:113\u20137.","journal-title":"Arch Pathol Lab Med."},{"key":"17978_CR5","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1016\/j.urology.2019.01.009","volume":"126","author":"A Nazemi","year":"2019","unstructured":"Nazemi A, Nassiri N, Pearce S, Daneshmand S. Testicular mesothelioma: an analysis of epidemiology, patient outcomes, and prognostic factors. Urology. 2019;126:140\u20134.","journal-title":"Urology."},{"key":"17978_CR6","doi-asserted-by":"publisher","first-page":"45","DOI":"10.4322\/acr.2014.007","volume":"4","author":"LG da Fonseca","year":"2014","unstructured":"da Fonseca LG, Marques DF, Takahashi TK, et al. Malignant paratesticular mesothelioma. Autops Case Rep. 2014;4:45\u201351.","journal-title":"Autops Case Rep."},{"key":"17978_CR7","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1016\/j.urology.2017.04.011","volume":"107","author":"P Recabal","year":"2017","unstructured":"Recabal P, Rosenzweig B, Bazzi WM, et al. Malignant mesothelioma of the tunica vaginalis testis: outcomes following surgical management beyond radical orchiectomy. Urology. 2017;107:166\u201370.","journal-title":"Urology."},{"key":"17978_CR8","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.humpath.2019.07.009","volume":"92","author":"KJ Butnor","year":"2019","unstructured":"Butnor KJ, Pavlisko EN, Sporn TA, Roggli VL. Mesothelioma of the tunica vaginalis testis. Hum Pathol. 2019;92:48\u201358.","journal-title":"Hum Pathol."},{"key":"17978_CR9","first-page":"1053","volume":"7","author":"N Zhang","year":"2017","unstructured":"Zhang N, Fu N, Peng S, Luo X. Malignant mesothelioma of the tunica vaginalis testis: a case report and literature review. Mol Clin Oncol. 2017;7:1053\u20136.","journal-title":"Mol Clin Oncol."},{"key":"17978_CR10","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.clgc.2022.09.001","volume":"21","author":"N Rathinasamy","year":"2023","unstructured":"Rathinasamy N, Menon S, Prakash G, et al. Multimodal management of testicular mesothelioma: a retrospective analysis from a tertiary cancer care centre. Clin Genitourin Cancer. 2023;21:124\u20137.","journal-title":"Clin Genitourin Cancer."},{"issue":"23","key":"17978_CR11","doi-asserted-by":"publisher","first-page":"3956","DOI":"10.3390\/cancers16233956","volume":"16","author":"N Rathinasamy","year":"2023","unstructured":"Stella S, Ceresoli GL, Dallari B, et al. Mesothelioma of the Tunica Vaginalis Testis: Diagnostic and Therapeutic Management. A Comprehensive Review. Cancers (Basel).2024;16(23):3956. https:\/\/doi.org\/10.3390\/cancers16233956","journal-title":"Cancers (Basel)."},{"key":"17978_CR12","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/j.jmoldx.2014.12.006","volume":"17","author":"DT Cheng","year":"2015","unstructured":"Cheng DT, Mitchell TN, Zehir A, et al. Memorial sloan kettering-integrated mutation profiling of actionable cancer targets (MSK-IMPACT): a hybridization capture-based next-generation sequencing clinical assay for solid tumor molecular oncology. J Mol Diagn. 2015;17:251\u201364.","journal-title":"J Mol Diagn."},{"key":"17978_CR13","doi-asserted-by":"publisher","first-page":"1548","DOI":"10.1158\/2159-8290.CD-18-0804","volume":"8","author":"J Hmeljak","year":"2018","unstructured":"Hmeljak J, Sanchez-Vega F, Hoadley KA, et al. Integrative molecular characterization of malignant pleural mesothelioma. Cancer Discov. 2018;8:1548\u201365.","journal-title":"Cancer Discov."},{"key":"17978_CR14","doi-asserted-by":"publisher","first-page":"12208","DOI":"10.1002\/cam4.5915","volume":"12","author":"P Bou-Samra","year":"2023","unstructured":"Bou-Samra P, Chang A, Azari F, et al. Epidemiological, therapeutic, and survival trends in malignant pleural mesothelioma: a review of the National Cancer Database. Cancer Med. 2023;12:12208\u201320.","journal-title":"Cancer Med."},{"key":"17978_CR15","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1002\/jso.21167","volume":"99","author":"D Rodriguez","year":"2009","unstructured":"Rodriguez D, Cheung MC, Housri N, Koniaris LG. Malignant abdominal mesothelioma: defining the role of surgery. J Surg Oncol. 2009;99:51\u20137.","journal-title":"J Surg Oncol."},{"key":"17978_CR16","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1186\/s12931-020-01449-2","volume":"21","author":"M Kojima","year":"2020","unstructured":"Kojima M, Kajino K, Momose S, et al. Possible reversibility between epithelioid and sarcomatoid types of mesothelioma is independent of ERC\/mesothelin expression. Respir Res. 2020;21:187.","journal-title":"Respir Res."},{"key":"17978_CR17","doi-asserted-by":"publisher","first-page":"1841","DOI":"10.1097\/JTO.0b013e3181f1cf2b","volume":"5","author":"MT Milano","year":"2010","unstructured":"Milano MT, Zhang H. Malignant pleural mesothelioma: a population-based study of survival. J Thorac Oncol. 2010;5:1841\u20138.","journal-title":"J Thorac Oncol."},{"key":"17978_CR18","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/S0140-6736(20)32714-8","volume":"397","author":"P Baas","year":"2021","unstructured":"Baas P, Scherpereel A, Nowak AK, et al. First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial. Lancet. 2021;397:375\u201386.","journal-title":"Lancet."},{"key":"17978_CR19","doi-asserted-by":"publisher","first-page":"2437","DOI":"10.1002\/(SICI)1097-0142(19981215)83:12<2437::AID-CNCR6>3.0.CO;2-G","volume":"83","author":"E Plas","year":"1998","unstructured":"Plas E, Riedl CR, Pfluger H. Malignant mesothelioma of the tunica vaginalis testis: review of the literature and assessment of prognostic parameters. Cancer. 1998;83:2437\u201346.","journal-title":"Cancer."},{"key":"17978_CR20","doi-asserted-by":"publisher","first-page":"e53","DOI":"10.11622\/smedj.2015053","volume":"56","author":"Y Akin","year":"2015","unstructured":"Akin Y, Bassorgun I, Basara I, Yucel S. Malignant mesothelioma of tunica vaginalis: an extremely rare case presenting without risk factors. Singapore Med J. 2015;56:e53\u20135.","journal-title":"Singapore Med J."},{"key":"17978_CR21","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1097\/PAP.0000000000000371","volume":"30","author":"KA Iczkowski","year":"2023","unstructured":"Iczkowski KA. Malignant mesothelioma of tunica vaginalis testis: update for 2022. Adv Anat Pathol. 2023;30:259\u201361.","journal-title":"Adv Anat Pathol."},{"key":"17978_CR22","doi-asserted-by":"publisher","first-page":"1446","DOI":"10.5858\/arpa.2022-0283-OA","volume":"147","author":"AJ Hocking","year":"2023","unstructured":"Hocking AJ, Thomas EM, Prabhakaran S, et al. Molecular characterization of testicular mesothelioma and the role of asbestos as a causative factor. Arch Pathol Lab Med. 2023;147:1446\u201350.","journal-title":"Arch Pathol Lab Med."},{"key":"17978_CR23","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1111\/his.14669","volume":"81","author":"WJ Anderson","year":"2022","unstructured":"Anderson WJ, Sholl LM, Fletcher CDM, et al. Molecular and immunohistochemical characterisation of mesothelioma of the tunica vaginalis. Histopathology. 2022;81:65\u201376.","journal-title":"Histopathology."},{"key":"17978_CR24","first-page":"2108","volume":"9","author":"PB Illei","year":"2003","unstructured":"Illei PB, Rusch VW, Zakowski MF, Ladanyi M. Homozygous deletion of CDKN2A and codeletion of the methylthioadenosine phosphorylase gene in the majority of pleural mesotheliomas. Clin Cancer Res. 2003;9:2108\u201313.","journal-title":"Clin Cancer Res."},{"key":"17978_CR25","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1016\/j.jtho.2019.12.111","volume":"15","author":"R Guo","year":"2020","unstructured":"Guo R, DuBoff M, Jayakumaran G, et al. Novel germline mutations in DNA damage repair in patients with malignant pleural mesotheliomas. J Thorac Oncol. 2020;15:655.","journal-title":"J Thorac Oncol."},{"key":"17978_CR26","doi-asserted-by":"publisher","first-page":"1254908","DOI":"10.3389\/fgene.2023.1254908","volume":"14","author":"C Pinto","year":"2023","unstructured":"Pinto C, Guerra J, Pinheiro M, et al. Combined germline and tumor mutation signature testing identifies new families with NTHL1 tumor syndrome. Front Genet. 2023;14:1254908.","journal-title":"Front Genet."}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-025-17978-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1245\/s10434-025-17978-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-025-17978-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T14:16:49Z","timestamp":1762352209000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1245\/s10434-025-17978-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,30]]},"references-count":26,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["17978"],"URL":"https:\/\/doi.org\/10.1245\/s10434-025-17978-3","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"value":"1068-9265","type":"print"},{"value":"1534-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,30]]},"assertion":[{"value":"15 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"PA has received honoraria from MJH Life Sciences. JS has received consulting fees from Janssen Research & Development, LLC; and has equity in Novocure and Pfizer, Inc. MGZ has received consulting fees from AZ, Orion, and Roche Diagnostics and honoraria for CME content from PER and HMP Global. Westchester Medical Center receives research funding from Merck, Sapience, and Werewolf for research conducted by MGZ. Memorial Sloan Kettering received research funding from the Department of Defense, the National Institutes of Health, Vivace, MedImmune, Precog, GlaxoSmithKline, Epizyme, Polaris, Sellas Life Sciences, Bristol Myers Squibb, Millenium\/Takeda, Curis, and Atara for research conducted by MGZ. MGZ serves as Chair of the Board of Directors of the Mesothelioma Applied Research Foundation, uncompensated. MO has received consulting roles\/honorarium with Novartis, Jazz, Pfizer, Targeted Oncology, OncLive, American Society for Radiation Oncology. Grant support from the Druckenmiller Foundation, Department of Defense and LUNGevity Foundation. Uncompensated scientific advisory board member for the Mesothelioma Applied Research Foundation. All other authors report no relevant disclosures.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosure"}}]}}